The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
A Japanese health ministry panel on July 30 approved the use of AstraZeneca’s COVID-19 vaccine for people aged 40 and above under the government’s emergency inoculation program, making it the third jab allowed under the scheme, after ones from Pfizer…
To read the full story
Related Article
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- Meiji Distributing AstraZeneca’s COVID-19 Vaccine in Japan
August 11, 2021
- Up to 580,000 Doses of AstraZeneca’s COVID Vaccine to Be Distributed in Tokyo
August 5, 2021
- Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
- Prefectural Governors Push AstraZeneca Vaccine Use
July 20, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
REGULATORY
- MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
- MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
- MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
- Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
- Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…